Physician profile
John T Port
NPI 1376517284
$967.33
in general payments reported to CMS, 2019-2025
15 companies · $6.00 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $206 · 2021: $154 · 2022: $54.03 · 2023: $158 · 2025: $6.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $164.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $346.79 | 2019-2023 | Evenity, Prolia |
| Horizon Therapeutics Plc | $151.80 | 2019-2022 | |
| Bioventus LLC | $131.66 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $94.37 | 2019-2023 | Euflexxa |
| Ascensia Diabetes Care US INC. | $51.55 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $29.06 | 2020 | |
| Ermi LLC | $25.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.70 | 2019 | |
| Orthofix Medical, INC. | $23.12 | 2022-2025 | Physio-Stim |
| Trice Medical, INC. | $17.89 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.73 | 2023 | Seglentis |
| Abbott Laboratories | $14.89 | 2021 | |
| Organogenesis INC. | $14.67 | 2021 | |
| Avanos Medical | $13.92 | 2023 | Trivisc Sodium Hyaluronate |
| Arthrosurface Incorporated | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Port listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.